Suppr超能文献

丙型肝炎病毒在肝细胞癌发生发展中的作用:从分子改变到可能的解决方案。

Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions.

作者信息

Bertino Gaetano, Malaguarnera Giulia, Frazzetto Evelise, Sciuto Alice, Inserra Gaetano, Zanghì Guido Nicola, Malaguarnera Michele

机构信息

Hepatology Unit, Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Catania 95123, Italy.

Research Center "the Great Senescence", University of Catania, Catania 95100, Italy.

出版信息

World J Hepatol. 2018 Jun 27;10(6):448-451. doi: 10.4254/wjh.v10.i6.448.

Abstract

There are several causes of hepatocellular carcinoma (HCC), but certainly the hepatitis C virus (HCV) is one of the most common. The HCV is able to contribute, both directly and indirectly, to the development of HCC. Determining early HCV clearance before an advanced liver disease develops, is absolutely necessary as this prevents the initiation of the cascade of events induced by HCV that may result in the development of HCC. The early treatment of the infection and the clearance of HCV represents today, in the age of the direct antiviral agents (DAAs), an extraordinary opportunity for true prevention of the development of HCV-related HCC.

摘要

肝细胞癌(HCC)有多种病因,但丙型肝炎病毒(HCV)无疑是最常见的病因之一。HCV能够直接或间接促进HCC的发生。在晚期肝病发展之前确定HCV早期清除是绝对必要的,因为这可防止由HCV诱导的一系列事件的发生,而这些事件可能导致HCC的发展。在直接抗病毒药物(DAA)时代,对HCV感染进行早期治疗并清除病毒,为真正预防HCV相关HCC的发生提供了一个绝佳机会。

相似文献

2
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
3
5
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
6
Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.
Cancer. 2015 Sep 1;121(17):2874-82. doi: 10.1002/cncr.29528. Epub 2015 Jun 16.
8
What Comes First: Treatment of Viral Hepatitis or Liver Cancer?
Dig Dis Sci. 2019 Apr;64(4):1041-1049. doi: 10.1007/s10620-019-05518-5.
9
Interferon-alpha-induced hepatitis C virus clearance restores p53 tumor suppressor more than direct-acting antivirals.
Hepatol Commun. 2017 Mar 28;1(3):256-269. doi: 10.1002/hep4.1025. eCollection 2017 May.

引用本文的文献

本文引用的文献

1
Mechanism of action and efficacy of LY2109761, a TGF-β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE.
Oncotarget. 2017 Dec 11;9(1):1130-1142. doi: 10.18632/oncotarget.23193. eCollection 2018 Jan 2.
2
Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection.
World J Hepatol. 2017 Dec 28;9(36):1305-1314. doi: 10.4254/wjh.v9.i36.1305.
3
Evaluation of health status in patients with hepatitis c treated with and without interferon.
Health Qual Life Outcomes. 2018 Jan 17;16(1):17. doi: 10.1186/s12955-018-0842-x.
4
Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.
6
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
7
Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis.
Aging Clin Exp Res. 2017 Feb;29(Suppl 1):185-190. doi: 10.1007/s40520-016-0653-z. Epub 2016 Nov 7.
9
Hepatocellular carcinoma and the risk of occupational exposure.
World J Hepatol. 2016 May 8;8(13):573-90. doi: 10.4254/wjh.v8.i13.573.
10
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验